Bill Lundberg, Merus CEO
June 4, 2021 12:00 PM EDT
R&D

#AS­CO21: Eli Lil­ly-part­nered Merus re­veals new da­ta for NRG1 fu­sion can­cers in­clud­ing pan­cre­at­ic and NSCLC

Max Gelman

Senior Editor

One of Eli Lil­ly’s newest R&D part­ners re­vealed some new da­ta at #AS­CO21 for an in-house pro­gram, and it’s one that could cov­er a broad …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times